Coagulation Cascade Protein-Protein Interfaces

The **coagulation cascade protein-protein interfaces** are the molecular contact points between distinct coagulation proteins that facilitate activation, inhibition, or assembly steps in the blood clotting process. These interfaces underpin the formation and regulation of enzyme complexes (such as intrinsic and extrinsic tenase, prothrombinase) required for the conversion of fibrinogen to fibrin, enabling hemostasis following vascular injury. While drugs can target individual proteins that participate in these interfaces, the interfaces themselves are not considered definitive therapeutic targets but are essential for understanding clotting disorders and for designing novel interventions capable of modulating protein-protein interactions within the cascade[2][3][4][5][6]. In summary, the requested "target" is conceptually valid for mechanistic studies and drug design *strategy*, but does not correspond to a single molecule or therapeutic target, and thus should not be entered as a canonical, structured target entity.

Inhibition of enzymatic activity (e.g., direct inhibition of thrombin, factor Xa); Enhancement of anticoagulant pathway (e.g., activating Protein C pathway); Inhibition of co-factor binding (e.g., blocking tissue factor interaction); Disruption of protein-protein interfaces critical for complex formation